|
Real-time Estimate
Cboe BZX
20:00:00 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 138.00 USD | 0.00% |
|
0.00% | - |
| 09-11 | Scholar Rock gets first FDA nod for rare muscle-wasting disease | RE |
| 09-11 | US FDA approves Scholar Rock's muscle weakness drug | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 994B | |||||
| 640B | - | - | - | ||
| 454B | |||||
| 337B | |||||
| 261B |
- Stock Market
- Stocks
- NOVN Stock
- Stock
- Charts Novartis AG
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
